Equifax (EFX) Competitors

84.1% of Charles River Associates shares are held by institutional investors. Comparatively, 96.2% of Equifax shares are held by institutional investors. 4.5% of Charles River Associates shares are held by insiders. Comparatively, 1.7% of Equifax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Charles River Associates pays an annual dividend of $2.28 per share and has a dividend yield of 1.6%. Equifax pays an annual dividend of $2.24 per share and has a dividend yield of 1.3%. Charles River Associates pays out 31.7% of its earnings in the form of a dividend. Equifax pays out 39.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Charles River Associates has raised its dividend for 7 consecutive years and Equifax has raised its dividend for 1 consecutive years. Charles River Associates is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Charles River Associates presently has a consensus target price of $245.00, suggesting a potential upside of 72.48%. Equifax has a consensus target price of $226.67, suggesting a potential upside of 32.92%. Given Charles River Associates' higher probable upside, equities research analysts clearly believe Charles River Associates is more favorable than Equifax.

Equifax has higher revenue and earnings than Charles River Associates. Charles River Associates is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.

Equifax has a net margin of 11.12% compared to Charles River Associates' net margin of 6.22%. Charles River Associates' return on equity of 26.02% beat Equifax's return on equity.

Charles River Associates has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Equifax has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

In the previous week, Charles River Associates had 3 more articles in the media than Equifax. MarketBeat recorded 17 mentions for Charles River Associates and 14 mentions for Equifax. Equifax's average media sentiment score of 1.03 beat Charles River Associates' score of 0.58 indicating that Equifax is being referred to more favorably in the news media.

In the previous week, Equifax had 11 more articles in the media than Aptiv. MarketBeat recorded 14 mentions for Equifax and 3 mentions for Aptiv. Equifax's average media sentiment score of 1.03 beat Aptiv's score of 0.69 indicating that Equifax is being referred to more favorably in the news media.

Equifax has lower revenue, but higher earnings than Aptiv. Equifax is trading at a lower price-to-earnings ratio than Aptiv, indicating that it is currently the more affordable of the two stocks.

94.2% of Aptiv shares are held by institutional investors. Comparatively, 96.2% of Equifax shares are held by institutional investors. 0.1% of Aptiv shares are held by company insiders. Comparatively, 1.7% of Equifax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aptiv currently has a consensus price target of $82.85, suggesting a potential upside of 7.71%. Equifax has a consensus price target of $226.67, suggesting a potential upside of 32.92%. Given Equifax's higher probable upside, analysts clearly believe Equifax is more favorable than Aptiv.

Aptiv has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Equifax has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Equifax has a net margin of 11.12% compared to Aptiv's net margin of 1.77%. Equifax's return on equity of 20.41% beat Aptiv's return on equity.

Aptiv pays an annual dividend of $0.88 per share and has a dividend yield of 1.1%. Equifax pays an annual dividend of $2.24 per share and has a dividend yield of 1.3%. Aptiv pays out 52.1% of its earnings in the form of a dividend. Equifax pays out 39.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Equifax has increased its dividend for 1 consecutive years. Equifax is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Equifax pays an annual dividend of $2.24 per share and has a dividend yield of 1.3%. Genpact pays an annual dividend of $0.75 per share and has a dividend yield of 2.3%. Equifax pays out 39.4% of its earnings in the form of a dividend. Genpact pays out 23.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Equifax has raised its dividend for 1 consecutive years and Genpact has raised its dividend for 6 consecutive years. Genpact is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Genpact had 6 more articles in the media than Equifax. MarketBeat recorded 20 mentions for Genpact and 14 mentions for Equifax. Equifax's average media sentiment score of 1.03 beat Genpact's score of 0.18 indicating that Equifax is being referred to more favorably in the media.

Equifax has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Genpact has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Equifax currently has a consensus price target of $226.67, suggesting a potential upside of 32.92%. Genpact has a consensus price target of $43.29, suggesting a potential upside of 33.87%. Given Genpact's higher possible upside, analysts clearly believe Genpact is more favorable than Equifax.

Equifax has a net margin of 11.12% compared to Genpact's net margin of 11.04%. Genpact's return on equity of 22.70% beat Equifax's return on equity.

96.2% of Equifax shares are held by institutional investors. Comparatively, 96.0% of Genpact shares are held by institutional investors. 1.7% of Equifax shares are held by company insiders. Comparatively, 1.6% of Genpact shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Equifax has higher revenue and earnings than Genpact. Genpact is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.

Equifax has a net margin of 11.12% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Equifax's return on equity.

IQVIA currently has a consensus price target of $224.13, suggesting a potential upside of 23.06%. Equifax has a consensus price target of $226.67, suggesting a potential upside of 32.92%. Given Equifax's higher probable upside, analysts plainly believe Equifax is more favorable than IQVIA.

In the previous week, Equifax had 6 more articles in the media than IQVIA. MarketBeat recorded 14 mentions for Equifax and 8 mentions for IQVIA. Equifax's average media sentiment score of 1.03 beat IQVIA's score of 0.10 indicating that Equifax is being referred to more favorably in the news media.

89.6% of IQVIA shares are held by institutional investors. Comparatively, 96.2% of Equifax shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 1.7% of Equifax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IQVIA has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Equifax has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

IQVIA has higher revenue and earnings than Equifax. IQVIA is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks.